Pharmacokinetics of dl-praeruptorin A after single-dose intravenous administration to rats with liver cirrhosis

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 3, 2011, Pages 210-215

  Zhang, Z ^a   Liang, X F ^a   Su, M Q ^a   Yang, Q ^a   Li, L P ^a   Zhang, X H ^a   Wang, X M ^a   Zhu, X ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

Dimethylnitrosamine; Pd Ia; Pharmacokinetic alteration; Rats

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; DIMETHYLNITROSAMINE; MESSENGER RNA; PRAERUPTORIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME KINETICS; LIVER BLOOD FLOW; LIVER CIRRHOSIS; LIVER MICROSOME; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE;

EID: 80053445061     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kozawa T, Sakai K, Uchida M, Okuyama T, Shibata S. Calcium antagonistic action of a coumarin isolated from Qian-Hu, a Chinese traditional medicine. J. Pharm. Pharmacol, 1981; 33: 317-320.
2. Chang TH, Liu XY, Zhang XH, Wang HL. Effects of dl-praeruptorin A on interleukin-6 level and Fas, bax, bcl-2 protein expression in ischemia-reperfusion myocardium. Acta Pharmacol. Sin, 2002; 23: 769-774.
3. Wang C, Chang TH, Zhang XH, Wang HL. Effects of dl-praeruptorin A on nucleus factor-κB and tumor necrosis factor-α expression in ischemia reperfusion hearts. Acta Pharmacol. Sin, 2004; 25: 35-40.
4. Chang H, Chu XY, Zou J, Chang TH. Effect of dl-praeruptorin A on desmin and vimentin content in rat ischemia/reperfusion myocardiocytes. Chin. Med. J, 2007; 120: 2256-2259.
5. Tu X, Miao L, Kang Y, Xia H, Tu JW, Wang Q, Tu Q, Wang JM, Hao H. Effect of dl-praeruptorin A on cultured neonatal rat ventricular cardiomyocytes with hypertrophy induced by endothelin-1. Methods Find. Exp. Clin. Pharmacol, 2009; 31: 231-236.
6. Zhang Z, Liu YY, Su MQ, Liang XF, Wang WF, Zhu X. Pharmacokinetics, tissue distribution and excretion study of dl-praeruptorin A in rats by liquid chromatography tandem mass spectrometry. Phytomedicine, 2011; 18: 527-532.
7. Veronese L, Rautaureau J, Sadler BM, Gillotin C, Petite JP, Pillegand B, Delvaux M, Masliah C, Fosse S, Lou Y, Stein DS. Single-dose pharmacokinetics of amprenavir, a human immunodefciency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob. Agents Chemother, 2000; 44: 821-826.
8. Kang KW, Kim YG, Cho MK, Bae SK, Kim CW, Lee MG, Kim SG Oltipraz regenerates cirrhotic liver through CCAAT/enhancer binding protein-mediated stellate cell inactivation. FASEB. J, 2002; 16: 1988-1990.
9. Jezequel AM, Mancini R, Rinaldesi ML. A morphological study of the early stages of hepatic fibrosis induced by low doses of dimethylnitrosamine in the rat. J. Hepatol, 1987; 6: 174-181.
10. Bae SK, Lee SJ, Lee J Y, Lee Y, Lee I, Kim SG, Lee MG. Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine. Int. J. Pharm, 2004; 275: 227-238.
11. Kamataki T, Kitagawa H. Effects of lyophilization and storage of rat liver microsomes on activity of aniline hydroxylase, contents of cytochrome b5 and cytochrome P-450 and aniline-induced P-450 difference spectrum. Jpn. J. Pharmacol, 1974; 24: 195-203.
12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem, 1976; 72: 248-254.
13. Ruan H, Zhang Z, Zhu X. Liquid chromatography tandem mass spectrometry pharmacokinetic study of dl-praeruptorin A in rat plasma. Biomed. Chromatogr, 2010; 24: 1193-1198.
14. Duggleby RG. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol, 1995; 249: 61-90.
15. Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J. Pharmacokinet. Biopharm, 1993; 21: 1-17.
16. Morgan DJ, McLean AJ. Therapeutic implications of impaired hepatic oxygen diffusion in chronic liver disease. Hepatology, 1991; 14:1280-1282.
17. Goeting NL, Fleming JS, Gallagher P, Walmsely BH, Karran SJ. Alterations in liver blood fow and reticuloendothelial function in progressive cirrhosis in the rat. J. Nucl. Med, 1986; 27: 1751-1754.
18. Ahn CY, Bae SK, Bae SH, Kim T, Jung YS, Kim YC, Lee MG, Shin WG. Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis. Brit. J. Pharmacol, 2009; 156: 1019-1028.